65,437 trials
Colorectal Cancer · Metastatic Cancer
Primary: Number of Participants With Objective Tumor Response Through Week 16 — 5 Participants
Influenza
Primary: Geometric Mean Titer 30 Days After the Last Study Vaccination — 235.44; 345.50; 652.99; 227.19 Titers
Multiple Sclerosis
Primary: Percentage of Keyhole Limpet Hemocyanin (KLH) Responders at Day 28 Post-Vaccination — 89; 83 percentage of participants
Beta-thalassemia Major · Hemosiderosis · Iron Overload
Primary: Percentage of Participants With Treatment Success From Core Baseline (BL) to Extension End of Study, by Baseline LIC Level and Age — 75.0; 100; 72.2; 50.0 percentage of…
Duchenne Muscular Dystrophy (DMD)
Primary: The Relative Change in Peak Systolic Radial Strain of the Left Ventricle (LV) Inferolateral Wall From Baseline (at Screening) to Week 52, Assessed by Color Doppler…
Geographic Atrophy · Age-Related Macular Degeneration · AMD
Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters
Arthritis, Psoriatic
Primary: Mean Time Interval Between Infusions During Maintenance Therapy — 57.03; 57.90; 58.59; 56.02 days
Hypertension · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26 — 0.12; 0.00; 0.40 Percentage
Lumbar Spinal Stenosis
Primary: Treatment Success Rates (At ≥ 5 Years) — 40.8; 30.8; 38.7; 53.8 percentage of participants
Clostridium Infections · Diarrhea
Primary: Cure Rate at End of Therapy — 86.7; 87.7 Percentage of Participants
Influenza
Primary: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A (6 Months to Less Than 3 Years) — 254; 167; 160; 111 Participants
Human Immunodeficiency Virus
Primary: Number of Patients With Virus That Develop Mutations Conferring Resistance to Lopinavir/Ritonavir, NRTIs or NNRTIs — 137; 68; 55; 122 Participants
Hypertension
Primary: Difference in Number of Patients Who Reached Target Blood Pressure
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.295; 0.012 Proportion of participants — p=< 0.0001
Colorectal Cancer
Primary: Disease-Free Survival (DFS) [Number of Events] — 379; 320; 563; 624 Participants